Announcing Syncromune's Landmark $100 Million Series A Funding for Groundbreaking Cancer Therapy Platform

We are thrilled to announce that Syncromune has successfully raised $100 million in its latest funding round, a significant milestone that underscores the growing confidence in our innovative approach to cancer treatment.

As a privately held, clinical-stage biopharmaceutical company, Syncromune is dedicated to revolutionizing the way we tackle metastatic solid tumor cancers through our groundbreaking in situ platform therapy.

Our flagship development, SYNC-T, combines partial tumor oncolysis with a multi-target biologic drug, uniquely designed to engage multiple mechanisms of action against cancer.

By promoting in situ immune activation while countering immunosuppression, SYNC-T aims to activate T cells, enabling the immune system to recognize and destroy cancer cells throughout the body and ultimately establish a long-lasting immune memory.

The recent funds will accelerate our clinical trials, specifically advancing our first two candidates, SV-101 and SV-102, which are currently progressing through Phase 1 trials.

This financing will not only support the continued development of SYNC-T but will also enable us to explore new avenues for amplifying our immune-oncology strategies.

With this substantial investment, Syncromune is poised to make meaningful strides in enhancing treatment options for patients battling aggressive cancers, ultimately aiming to achieve higher response rates and improved survival outcomes.

We are deeply grateful to our investors for their support and belief in our mission, and we look forward to sharing our progress on this transformative journey.